Cite
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
MLA
Mateos, Maria-Victoria, et al. “Results from the Randomized Phase III DREAMM-7 Study of Belantamab Mafodotin (Belamaf) + Bortezomib, and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM).” Journal of Clinical Oncology, vol. 42, Feb. 2024, p. 439572. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.36_suppl.439572.
APA
Mateos, M.-V., Robak, P., Hus, M., Xia, Z., Zherebtsova, V., Ward, C., Ho, P. J., Hajek, R., Kim, K., Dimopoulos, M. A., Cerchione, C., Riccio, A., McKeown, A., Rogers, R., Baig, H., Eccersley, L., Roy-Ghanta, S., Opalinska, J., & Hungria, V. (2024). Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology, 42, 439572. https://doi.org/10.1200/JCO.2024.42.36_suppl.439572
Chicago
Mateos, Maria-Victoria, Pawel Robak, Marek Hus, Zhongjun Xia, Vera Zherebtsova, Christopher Ward, P. Joy Ho, et al. 2024. “Results from the Randomized Phase III DREAMM-7 Study of Belantamab Mafodotin (Belamaf) + Bortezomib, and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM).” Journal of Clinical Oncology 42 (February): 439572. doi:10.1200/JCO.2024.42.36_suppl.439572.